OvaGene, Hitachi Collaborate on mRNA Biomarkers for Gynecological Cancers
By LabMedica International staff writers Posted on 01 Oct 2014 |
Ovagene (Irvine, CA, USA), a molecular diagnostics firm, will collaborate with Hitachi Chemical Research Center (Irvine, CA, USA) to develop novel mRNA-based signatures for gynecological cancers. The collaboration aims to develop tests for the analysis of tumor mRNA within exosomes and microvessels in blood and vaginal fluids. Financial and other terms of the deal were not disclosed.
The agreement, which leverages Hitachi’s exosome technologies and OvaGene’s research, clinical validation, and translational expertise, focuses on the development of blood-based mRNA signatures to guide the selection of therapy and to monitor therapy response for ovarian cancer. The partners will also seek to identify novel mRNA signatures for diagnosing the early onset of ovarian or endometrial cancer in high-risk women, according to OvaGene spokespersons.
OvaGene reported that although early detection is the key to successfully treating ovarian and endometrial cancers, there currently are no simple, cost-effective, and reliable tests for early detection. Also lacking are approaches for quickly determining whether a specific therapy is effective for a patient.
William Ricketts, CSO of OvaGene, said, “These assays are developed to use blood or body fluid samples, making them easier to obtain from patients than surgical specimens.” He added that technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) have resulted in less invasive methods of obtaining samples and can be used to develop robust and reproducible laboratory tests. “Less invasive sample collection can potentially increase the number of patients who will be tested, therefore increasing the number of cancer patients identified at an earlier stage of disease.”
Related Links:
Ovagene
Hitachi Chemical Research Center
The agreement, which leverages Hitachi’s exosome technologies and OvaGene’s research, clinical validation, and translational expertise, focuses on the development of blood-based mRNA signatures to guide the selection of therapy and to monitor therapy response for ovarian cancer. The partners will also seek to identify novel mRNA signatures for diagnosing the early onset of ovarian or endometrial cancer in high-risk women, according to OvaGene spokespersons.
OvaGene reported that although early detection is the key to successfully treating ovarian and endometrial cancers, there currently are no simple, cost-effective, and reliable tests for early detection. Also lacking are approaches for quickly determining whether a specific therapy is effective for a patient.
William Ricketts, CSO of OvaGene, said, “These assays are developed to use blood or body fluid samples, making them easier to obtain from patients than surgical specimens.” He added that technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) have resulted in less invasive methods of obtaining samples and can be used to develop robust and reproducible laboratory tests. “Less invasive sample collection can potentially increase the number of patients who will be tested, therefore increasing the number of cancer patients identified at an earlier stage of disease.”
Related Links:
Ovagene
Hitachi Chemical Research Center
Latest Molecular Diagnostics News
- Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays